*FDA APPROVES COMPASSIONATE USE OF URCOSIMOD (0.05%) FOR THE TREATMENT OF NEUROPATHIC CORNEAL PAIN
*OKYO PHARMA LTD - TO INITIATE 120-PATIENT STUDY OF URCOSIMOD TO TREAT NCP THIS YEAR
((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))
Source Date/Time = 23-JAN-202612:00:00.157 GMT